FDA Approves New Type 1 Diabetes Treatment That Eliminates The Need For Insulin

Life with type 1 diabetes can be tough, as it requires regular shots and medical care.

According to the Centers for Disease Control and Prevention, more than 37 million people in the United States have diabetes.

In fact, one in 10 adults throughout the world now has diabetes!

The CDC explains, “If you have type 1 diabetes, your pancreas doesn’t make insulin or makes very little insulin…Without insulin, blood sugar can’t get into cells and builds up in the bloodstream. High blood sugar is damaging to the body and causes many of the symptoms and complications of diabetes.”

People with type 1 diabetes require daily insulin shots, and some wear an insulin pump.

Research for diabetes is ongoing, and recent advancements are truly changing the game. Back in 2022, for instance, the FDA approved the first drug capable of delaying type 1 diabetes.

Now, the FDA has approved a new drug called Lantidra that’s designed to manage low blood sugar in people with type 1 diabetes. The drug allows people with type 1 diabetes to forgo insulin.

“Today’s approval, the first-ever cell therapy to treat patients with type 1 diabetes, provides individuals living with type 1 diabetes and recurrent severe hypoglycemia an additional treatment option to help achieve target blood glucose levels,” Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said in a press release.

Lantidra is “the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes.” Lantidra was approved after its safety was assessed in two non-randomized trials with 30 participants who live with type 1 diabetes and hypoglycemic unawareness.

Let’s Support Diabetes Research Every Day! Click to Give Here – It’s FREE! When you click, GreaterGood funds research and support for those in need.